Leo Pharma poised to post DKK billion figure into San Francisco drug: "We're waiting for the trial results"
In around a year, Leo pharma will have access to pivotal trial data from a drug candidate study for which the company has secured purchasing rights.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
For two years, Leo Pharma has stood ready at the sidelines of the US biotech company Pellepharm, which has the possibility of becoming the skin disease specialists' way onto the rare disease arena.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Innovation Lab moves closer to its parent company
For subscribers
Leo Pharma poised to market new drug every 2-3 years
For subscribers
.jpg)
.jpg&w=384&q=75)
